CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia

References

• I De Meester, S Korom, J Van Damme, S ScharpeÂ. CD26, let it cut or cut it down. Immunol Today 1999;20:367–375.
   PubMedGoogle Scholar
• T KaÈhne, U Lendeckel, S Wrenger, K Neubert, S Ansorge, D Reinhold. Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth. Int J Mol Med 1999;4:3–15.
   PubMed Web of Science ®Google Scholar
• R Mentlein. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 1999;85:9–24.
   PubMed Web of Science ®Google Scholar
• T Oravecz, M Pall, G Roderiquez, MD Gorrell, M Ditto, NY Nguyen, R Boykins, E Unsworth, MA Norcross. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997;186:1865–1872.
   PubMed Web of Science ®Google Scholar
• P Proost, I De Meester, D Schols, S Struyf, AM Lambeir, A Wuyts, G Opdenakker, E De Clercq, S Scharpe, J Van Damme. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273:7222–7227.
   PubMed Web of Science ®Google Scholar
• T Shioda, H Kato, Y Ohnishi, K Tashiro, M Ikegawa, EE Nakayama, H Hu, A Kato, Y Sakai, H Liu, T Honjo, A Nomoto, A Iwamoto, C Morimoto, Y Nagai. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998;95:6331–6336.
   PubMed Web of Science ®Google Scholar
• P Proost, S Struyf, D Schols, G Opdenakker, S Sozzani, P Allavena, A Mantovani, K Augustyns, G Bal, A Haemers, AM Lambeir, S ScharpeÂ, J Van Damme, I De Meester. Truncation of macrophage-derived chemokine by CD26/dipeptidylpeptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988–3993.
   PubMed Web of Science ®Google Scholar
• S Struyf, P Proost, D Schols, E De Clercq, G Opdenakker, JP Lenaerts, M Detheux, M Parmentier, I De Meester, S ScharpeÂ, J Van Damme. CD26/dipeptidyl-peptidase IV downregulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor. J Immunol 1999;162:4903–4909.
   PubMed Web of Science ®Google Scholar
• R Mentlein, P Dahms, D Grandt, R KruÈger. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993;49:133–144.
   PubMed Web of Science ®Google Scholar
• LA Frohman, TR Downs, EP Heimer, AM Felix. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989;83:1533–1540.
   PubMed Web of Science ®Google Scholar
• J Bongers, T Lambros, M Ahmad, EP Heimer. Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim Biophys Acta 1992;1122:147–153.
   PubMed Web of Science ®Google Scholar
• R Mentlein, B Gallwitz, WE Schmidt. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagons like peptide-1 (7 ± 36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993;214:829–835.
   PubMedGoogle Scholar
• TJ Kieffer, CH McIntosh, RA Pederson. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136:3585–3596.
   PubMed Web of Science ®Google Scholar
• DJ Drucker, Q Shi, A Crivici, M Sumner-Smith, W Tavares, M Hill, L DeForest, S Cooper, PL Brubaker. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997;15:673–677.
   PubMed Web of Science ®Google Scholar
• S Wrenger, T KaÈhne, C Bohuon, W WegloÈhner, S Ansorge, D Reinhold. Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett 2000;466:155–159.
   PubMed Web of Science ®Google Scholar
• SA Hinke, JA Pospisilik, HU Demuth, S Mannhart, K Kuhn-Wache, T Hoffmann, E Nishimura, RA Pederson, CH McIntosh. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem 2000;275:3827–3834.
   PubMed Web of Science ®Google Scholar
• MA Shipp, AL Look. Hematopoietic differentiation antigens that are membrane associated enzymes: Cutting is the key!. Blood 1993;82:1052–1070.
   PubMed Web of Science ®Google Scholar
• F Buhling, U Junker, D Reinhold, K Neubert, L Jager, S Ansorge. Functional role of CD26 on human B lymphocytes. Immunol Lett 1995;45:47–51.
   PubMed Web of Science ®Google Scholar
• F Buhling, D Dunz, D Reinhold, AJ Ulmer, M Ernst, HD Flad, S Ansorg. Expression and functional role of dipeptidyl peptidase IV on human natural killer cells. Nat Immun 1994;13:270–279.
   PubMedGoogle Scholar
• T Tanaka, JS Duke-Cohan, J Kameoka, A Yaron, I Lee, SF Schlossman, C Morimoto. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994;91:3082–3086.
   PubMed Web of Science ®Google Scholar
• RP Dong, J Kameoka, M Hegen, T Tanaka, Y Xu, SF Schlossman, C Morimoto. Characterization of adenosine deaminase binding to human CD26 on T-cells and its biologic role in immune response. J Immunol 1996;156:1349–1355.
   PubMed Web of Science ®Google Scholar
• RP Dong, K Tachibana, M Hegen, Y Munakata, D Cho, SF Schlossman, C Morimoto. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997;159 (12):6070–6076.
   PubMed Web of Science ®Google Scholar
• S Kobayashi, K Ohnuma, M Uchiyama, K Iino, S Iwata, NH Dang, C Morimoto. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. Blood 2004;103 (3):1002–1010.
   PubMed Web of Science ®Google Scholar
• T Ishii, K Ohnuma, A Murakami, N Takasawa, S Kobayashi, NH Dang, SF Schlossman, C Morimoto. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001;98 (21):12138–12143.
   PubMed Web of Science ®Google Scholar
• NH Dang, C Morimoto. CD26: An expanding role in immune regulation and cancer. Histol Histopathol 2002;17:1213–1226.
   PubMed Web of Science ®Google Scholar
• A Šedo, R Malík. Dipeptidyl peptidase IV—like molecules: Homologous proteins or homologous activities?. Biochim Biophys Acta 2001;550:107–116.
   Web of Science ®Google Scholar
• P Busek, R Malik, A Sedo. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 2004;36 (3):408–421.
   PubMed Web of Science ®Google Scholar
• NA Thornberry, AE Weber. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr Top Med Chem 2007;7 (6):557–568.
   PubMed Web of Science ®Google Scholar
• D Kim, L Wang, M Beconi, GJ Eiermann, MH Fisher, H He, GJ Hickey, JE Kowalchick, B Leiting, K Lyons, F Marsilio, ME McCann, RA Patel, A Petrov, G Scapin, SB Patel, RS Roy, JK Wu, MJ Wyvratt, BB Zhang, L Zhu, NA Thornberry, AE Weber. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin -7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141–151.
   PubMed Web of Science ®Google Scholar
• B Bani. Leukemia diagnosis. London: Blackwell Science; 1997.
   Google Scholar
• MC Béné, G Castoldi, W Knapp, WD Ludwig, E Matutes, A Orfao, MB van't Veer. Proposals for the immunological classification of acute leukemias. European Group for the immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783–1786.
   PubMed Web of Science ®Google Scholar
• PL Amlot, F Tahami, D Chinn, E Rawlings. Activation antigen expression on human T cells. I. Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue. Clin Exp Immunol 1996;105 (1):176–182.
   PubMed Web of Science ®Google Scholar
• M Klobusická, O Babusiková. Immunophenotypic characteristics of T-acute lymphoblastic leukemia cells in relation to DPPIV enzyme expression. Neoplasma 1998;45 (4):237–242.
   PubMed Web of Science ®Google Scholar
• M Klobusická, O Babusiková. Expression of CD26 and DPPIV in T-acute lymphoblastic leukemia: Comparison of immunocytochemistry with enzyme cytochemistry. Neoplasma 1999;46 (5):299–303.
   PubMed Web of Science ®Google Scholar
• P Ruiz, N Zacharievich, M Shenkin. Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations. Clin Diagn Lab Immunol 1998;5 (3):362–368.
   PubMedGoogle Scholar